AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery large
Description: 1 million dollar lottery
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash small
Description: smaller guaranteed cash amount
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash medium
Description: mid sized quarenteed cash amount
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash large
Description: large quarenteed cash amount
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for exercise financial incentive study
Description: financial incentives earned when increasing exercise behaviors
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for exercise social incentive study
Description: social incentives earned when increasing exercise behaviors
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for sleep social incentive study
Description: social incentives earned when increasing sleep
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for sleep financial incentive
Description: Financial incentives earned when increasing sleep
Study NCT04848077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
Study NCT04848077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
Study NCT04859569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01011
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study NCT04859569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY01011
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study NCT04859569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study NCT06250244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1011
Description: \[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.
Study NCT04865341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB
Description: Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
Study NCT04865341 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-Only Control
Description: Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
Study NCT06151379 — intervention group
Intervention type: OTHER
Intervention: Neoadjuvant therapy
Description: To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Study NCT05366855 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imsidolimab
Description: Solution for infusion; Solution for injection
Study NCT05366855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study NCT05063253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, SC, once weekly
Study NCT05063253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, SC, once weekly
Study NCT06312709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)
Description: teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.
Study NCT06312709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
Study NCT05143697 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wellness Coaching for Families and Kids
Description: The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
Study NCT04976244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata
Study NCT06442007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation - single session intervention (BA-SSI)
Description: Single session intervention
Study NCT06442007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4-session Mindset intervention
Description: This is comprised of 4 sessions.
Study NCT06381544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy application
Description: Applying lemon, orange and frankincense oils via inhalation
Study NCT05041010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL group
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
Study NCT05041010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
Study NCT05037630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Digital Tool for Problematic Alcohol Use
Description: See arm/group-description
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
Study NCT05036226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
Study NCT06228391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ketamine
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.
Study NCT06228391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.
Study NCT04972305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and ergonomics
Description: 12 week exercise and fit bike
Study NCT04972305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomics
Description: Fit bike
Study NCT05565495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Study NCT06218160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone combined with ropivacaine
Description: 1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
Study NCT06218160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
Study NCT05922384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-7SHRNA injection solution
Description: Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
Study NCT05889975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interdental brush
Description: cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
Study NCT05889975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single tufted brush
Description: cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
Study NCT05751785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
Study NCT05751785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave Therapy
Description: A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
Study NCT05751785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm\^2 that is applied in a serpentine manner over the site of injury.
Study NCT05090670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy
Description: Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy
Study NCT05090670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replica Knee Brace
Description: Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
Study NCT05501977 — intervention group
Intervention type: PROCEDURE
Intervention: thoracotomy
Description: thoracic surgery for pulmonary diseases
Study NCT05833490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS)
Description: Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at \~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
Study NCT05833490 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Priming
Description: Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
Study NCT06329973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib in combination with Sintilimab and CAPEOX
Description: Different doses of fruquintinib combined with sintilimab and CAPEOX
Study NCT05889975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water irrigator
Description: using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
Study NCT04419272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.
Study NCT04419272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
Study NCT04419272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
Study NCT06388772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD106 Injection
Description: 250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
Study NCT06388772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT05843409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
Study NCT05617430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W
Study NCT05617430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1, Q3W
Study NCT05617430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: 7.5mg/kg IV d1, Q3W
Study NCT06131489 — intervention group
Intervention type: OTHER
Intervention: Segmental bowel resection combined with the DEP regimen
Description: Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOC Group B
Description: Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-COMRAD 1 and 2 Group B
Description: polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R-CYM 1 and 2 Group B
Description: polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOC Group C
Description: cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD CPR 1 and 2
Description: methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R CYVE 1 and 2
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R CYVE-MTX 1 and 2
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD CP
Description: dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-Cytarabine/etoposide
Description: polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD CP
Description: polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-AVD-R 1 and 2: COHORT IIa
Description: brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-2
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-4 SER
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-AVD-R
Description: Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;